Glaukos Corporation Reports Strong Q2 Growth Amid Ongoing Challenges and Strategic Acquisitions

Company Overview: Glaukos Corporation (NYSE: GKOS), based in Aliso Viejo, California, is an ophthalmic pharmaceutical and medical technology company focused on developing therapies for glaucoma, corneal disorders, and retinal diseases.

Recent Developments: - Acquired Mobius Therapeutics for $12.4 million, with potential additional payments of $80 million based on sales milestones. - Purchased a 40,000-square-foot building adjacent to its facilities for $16.6 million to support future expansion.

Income Statement Highlights:

• Net Sales (Q2 2025): $124.1 million, a 30% increase from $95.7 million in Q2 2024.
• Net Sales (Six Months 2025): $230.8 million compared to $181.3 million in the prior year, a 27% increase.
• Gross Profit: $97.2 million, representing a gross margin of 78%, improved from 76% in the previous year.
• Operating Expenses: Increased to $119.9 million from $103.1 million a year ago.
• Loss from Operations: $22.7 million, reflecting a decrease from $30.0 million in Q2 2024.
• Net Loss: $19.7 million in Q2 2025 compared to $50.5 million in Q2 2024.

Positive Aspects:

• Significant growth in net sales, particularly in the glaucoma product line.
• Improved gross margins indicating effective cost management.
• Enhanced cash position with $100.8 million in cash and $173.9 million in short-term investments.

Negative Aspects:

• Continued net losses and an accumulated deficit of $783.2 million as of June 30, 2025.
• Operating expenses are rising, impacting overall financial performance.
• Potential disruptions from ongoing supply chain issues and macroeconomic conditions affecting operational efficiency.

Market Challenges:

• Risk of reduced Medicare payment rates affecting revenue for glaucoma procedures.
• Increased competition and changing regulatory landscape may impact future profitability.
• Potential impacts from foreign currency fluctuations affecting international sales.

Outlook: Glaukos is positioned for growth with innovative products like the iDose TR and increasing international sales but faces challenges with net losses and market volatility. The success of recent acquisitions and the regulation process will be key to achieving sustainable profitability.